quinazolines has been researched along with carboplatin in 170 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.59) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 62 (36.47) | 29.6817 |
| 2010's | 105 (61.76) | 24.3611 |
| 2020's | 2 (1.18) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, B | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Vasey, PA | 1 |
| Carbone, D; Heelan, RT; Johnson, DH; Kris, MG; Krozely, P; Krug, LM; Miller, VA; Ochs, J; Perez, W; Pizzo, B; Sandler, A; Smith, R; Tyson, L | 1 |
| Sandler, A | 1 |
| Averbuch, SD; Fandi, A; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Krebs, AD; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Oliff, I; Reeves, JA; Rosell, R; Scagliotti, G; Schiller, JH; Wolf, MK | 1 |
| Edelman, MJ | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Kosmidis, P; Kourea, H; Lambropoulos, S; Linardou, H; Markopoulos, C; Mavroudis, D; Papadimitriou, C; Papadopoulos, S; Pavlidis, N; Pectasides, D; Razis, E; Skarlos, D | 1 |
| Amler, LC; Eberhard, DA; Goddard, AD; Heldens, SL; Herbst, RS; Hillan, KJ; Ince, WL; Jänne, PA; Januario, T; Johnson, BE; Johnson, DH; Klein, P; Miller, VA; Ostland, MA; Ramies, DA; Sebisanovic, D; Seshagiri, S; Stinson, JA; Zhang, YR | 1 |
| Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT | 1 |
| Bidart, JM; Duvillard, P; Lacroix, L; Motté, N; Pautier, P; Saulnier, P; Soria, JC | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Reck, M | 2 |
| Fujii, Y; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
| Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH | 1 |
| Breau, JL; Brechot, JM; Chouahnia, K; Des-Guetz, G; Morere, JF; Saintigny, P | 1 |
| Abrams, DI; Cheng, J; Dhruva, A; Kwong, M; Luce, JA | 1 |
| Katakami, N | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Beeram, M; Hamilton, M; Hammond, LA; Hidalgo, M; Kreisberg, JI; Mita, MM; Nadler, P; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Wolf, J; Wood, D | 1 |
| Sugio, K; Uramoto, H; Yasumoto, K | 1 |
| Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Tsukuda, M | 1 |
| Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W | 1 |
| Gillani, JA; Iqbal, M; Khan, A; Nasreen, S; Samad, A | 1 |
| Carty, K; Gabra, H; Gore, M; Guastalla, JP; Kaye, S; Lauraine, EP; Paul, J; Rustin, G; Vasey, PA; Wilson, R | 1 |
| Aldape, K; Colman, H; Conrad, C; de Groot, JF; Gilbert, MR; Groves, MD; Hanna, TA; Hess, KR; Ictech, S; Levin, V; Puduvalli, VK; Yung, WK | 1 |
| Fukai, M; Fushitani, K; Kimura, H; Mori, M; Naka, N; Nakagawa, M; Nakazawa, Y; Namba, Y; Niinaka, M; Okada, T; Yano, Y; Yokota, S | 1 |
| Ishikawa, H; Kikuchi, N; Ohara, G; Satoh, H; Sekizawa, K | 1 |
| Alvarez, RD; Barnes, MN; Estes, JM; Kimball, KJ; Kirby, TO; Koch, KM; Matei, DE; Numnum, TM; Zamboni, WC | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Bunn, PA; Dziadziuszko, R; Gajapathy, S; Hirsch, FR; Lin, M; O'Neill, V; Skokan, M; Varella-Garcia, M; Xiao, Y | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J | 1 |
| Azzoli, CG; Brahmer, JR; Fogle, M; Ginsberg, M; Kris, MG; Miller, VA; Milton, DT; Riely, GJ; Rizvi, NA; Rosen, N; Rudin, CM; Senturk, E; Seshan, VE; Sirotnak, FM; Solit, DB | 1 |
| Clynes, M; Corkery, B; Crown, J; O'Donovan, N | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR | 1 |
| Altman, RB; Brunak, S; Hansen, NT | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Manegold, C | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Armour, AA; Chewaskulyong, B; Chu, DT; Duffield, EL; Fukuoka, M; Han, B; Ichinose, Y; Jiang, H; Margono, B; Mok, TS; Nishiwaki, Y; Ohe, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Watkins, CL; Wu, YL; Yang, CH; Yang, JJ | 1 |
| Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Arnold, A; Ciuleanu, TE; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Frymire, E; Gauthier, I; Goss, GD; Ho, C; Laberge, F; Laurie, SA; Lee, CW; Leighl, NB; Noble, J; Seymour, L; Shepherd, FA; Vincent, MD; Walde, D; Zukin, M | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Inoue, F; Momosaki, N; Morizono, G; Takenaka, T; Tanaka, T; Tomisaki, S | 1 |
| Iwakawa, J; Kawamata, Y; Kumamoto, T; Suetsugu, T; Tanoue, A | 1 |
| Ballatori, E; Fatigoni, S; Roila, F | 1 |
| Ando, M; Fukuoka, M; Hida, T; Ichinose, Y; Iwamoto, Y; Kashii, T; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Nakagawa, K; Okamoto, I; Sasaki, J; Sato, T; Satouchi, M; Sawa, T; Seto, T; Takayama, K; Takeda, K; Yamamoto, N | 1 |
| Amir, E; Seruga, B; Tannock, I | 1 |
| Takano, T | 1 |
| Neal, JW | 1 |
| Blumenschein, GR; Herbst, RS; Kim, ES; Lu, C; Lum, BL; Malik, M; Oh, YW; Papadimitrakopoulou, VA; Tran, HT; Zinner, RG | 1 |
| Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O | 1 |
| Athanasiou, A; Bardi, G; Chandrinou, H; Stathopoulos, GP; Trafalis, D | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Ando, M; Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Miyazawa, H; Morita, S; Nukiwa, T; Ogura, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Tanaka, T; Yoshimori, K; Yoshizawa, H | 1 |
| Ellard, SL; Fisher, B; Grimshaw, R; Hirte, H; Oza, A; Seymour, L; Swenerton, K; Tsao, M | 1 |
| Aebersold, DM; Bernier, J; Bucher, SE; Ciernik, IF; Glanzmann, C; Lippuner, T; Lombrieser, N; Lütolf, UM; Ries, G; Rothschild, S; Zouhair, A | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Albain, KS; Atkins, JN; Chansky, K; Crowley, JJ; Dakhil, SR; Franklin, WA; Gandara, DR; Herbst, RS; Hirsch, FR; Kelly, K; Kim, ES; Mack, PC; Redman, M | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Bagust, A; Boland, A; Brown, T; Dickson, R; Dundar, Y; Hockenhull, J; Oyee, J; Proudlove, C; Ramani, VS | 1 |
| Al-Khater, AM; Rasul, KI | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Goff, B; Holmberg, LA; Veljovich, D | 1 |
| Behrens, RJ; Cannon, MW; Friedman, EL; Gross, GG; Hillman, SL; Jatoi, A; Mc Kean, H; Rowland, KM; Sborov, MD; Stella, PJ | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| de Marinis, F; Di Maio, M; Gridelli, C; Ricciardi, S; Rossi, A | 1 |
| Kimura, H; Nakagawara, A; Nakajima, T; Yasufuku, K; Yoshino, I | 1 |
| Shepherd, FA | 1 |
| Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 1 |
| Gaafar, RM; Hasan, B; Papamichael, D; Scagliotti, GV; Surmont, VF; Torri, V; Van Klaveren, RJ; van Meerbeeck, JP; Welch, JJ | 1 |
| Bunn, PA; Camidge, DR; Camidge, R; Dziadziuszko, R; Eisen, T; Franklin, WA; Hirsch, FR; Kabbinavar, F; Martins, R; Richardson, F; Richardson, K; Rusk, J; Schnell, FM; Sternberg, DW; Varella-Garcia, M; Wacker, B | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Crane, K | 1 |
| Alecci, C; Assaraf, YG; Destro, A; Giancola, F; Gianoncelli, L; Giovannetti, E; Leon, LG; Lorenzi, E; Peters, GJ; Roncalli, M; Santoro, A; Smid, K; Zucali, PA | 1 |
| Armour, A; Chen, YM; Chu, DT; Duffield, E; Fukuoka, M; Kuo, HP; Lam, KC; Liao, M; Magill, P; Negoro, S; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Grosso, F; Scagliotti, GV | 1 |
| Aamdal, S; Barrett, S; Barriuso, J; Boven, E; Burke, W; de Vries, EG; Emeribe, U; Freyer, G; Hartog, V; Jones, R; Kaye, S; Kristensen, GB; Kuenen, B; Nyakas, M; Pietersma, D; Pujade-Lauraine, E; Ruijter, R; Sandhu, S; Stuart, M; Tan, DS | 1 |
| Juergens, R; Levine, MN | 1 |
| Capelletti, M; Crawford, J; Edelman, MJ; Gu, L; Jänne, PA; Kratzke, R; Miller, VA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Kato, T; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yokomizo, Y; Yoshizawa, H | 1 |
| Guo, Z; Li, J | 1 |
| Mason, DP | 1 |
| Bepler, G; Chen, W; Ghosh, D; Norkin, M; Raghunathan, TE; Sargent, DJ | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Gui, T; Shen, K | 1 |
| Chen, RC; Halle, J; Higginson, DS; Marks, LB; Morris, DE; Pham, E; Rosenman, JG; Socinski, MA; Stefanescu, M; Tracton, G | 1 |
| Chu, DT; Duffield, E; Fukuoka, M; Han, B; Jiang, H; Liao, M; Liu, X; Mok, T; Wu, YL; Zhang, L; Zhou, C | 1 |
| Aiken, RD; Akerley, WA; Beelen, AP; Colman, H; De Groot, JF; Evans, BA; Glantz, M; Grossmann, KF; Jensen, RL; Matsuoko, Y; Olsen, JJ; Olson, JJ; Yu, M | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yoshimori, K; Yoshizawa, H | 1 |
| Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F | 1 |
| Bell, R; Khasraw, M | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Adam-Klages, S; Arnold, N; Caliebe, A; Eckmann-Scholz, C; Fredrik, R; Hilpert, F; Ma, Y; Schem, C; Sebens, S; Weimer, J | 1 |
| Clément-Duchêne, C; Lamaze, R; Martinez, L | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Chu, DT; Fukuoka, M; Mok, TS; Rukazenkov, Y; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ | 1 |
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Stinchcombe, TE | 1 |
| Candon, D; Crown, J; Healy, J | 1 |
| Bosdet, I; Ho, C; Ionescu, D; Karsan, A; Laskin, JJ; Mariano, C; Melosky, B; Murray, N; Sun, S; Zhai, Y | 1 |
| Arnold, AM; Boyer, MJ; Bradbury, PA; Chen, EX; Clingan, P; Ding, K; Ellis, PM; Fenton, D; Goss, GD; Hirsh, V; Laberge, F; Laurie, SA; Lee, CW; Montenegro, A; Seymour, L; Shepherd, FA; Solomon, BJ; Stockler, MR; Zukin, M | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Ishii, Y; Isobe, H; Kobayashi, K; Maemondo, M; Minegishi, Y; Sugawara, S; Watanabe, S; Yoshizawa, H | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Bohnet, S; Deppermann, KM; Eiff, MV; Fischer, JR; Heigener, DF; Koester, W; Kortsik, C; Pawel, JV; Reck, M; Schnabel, PA; Thomas, M | 1 |
| Fang, Q; Li, N; Ou, W; Sun, HB; Wang, BX; Wang, SY; Ye, X; Zhang, L; Zhang, SL | 1 |
| Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C | 1 |
| Chang, J; Feng, Y; Luo, Z; Peng, W; Qiao, J; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, J | 1 |
| Bogart, J; Bradley, J; Hodgson, L; Jänne, PA; Katragadda, S; Kong, FM; Lilenbaum, R; Masters, G; Samuels, M; Vokes, E; Wang, X | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Atagi, S; Hirashima, T; Kurata, K; Minomo, S; Nakatani, T; Okamoto, N; Okishio, K; Omachi, N; Saijo, N; Shiroyama, T; Suzuki, H; Takeuchi, N; Tamiya, A; Tamiya, M; Tsuji, T | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Ito, K; Kinoshita, I; Kobayashi, K; Kurihara, M; Maemondo, M; Minato, K; Morita, S; Nishitsuji, M; Nukiwa, T; Oizumi, S; Sugawara, S; Yoshizawa, H | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Fujita, Y; Fukuhara, T; Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Miyauchi, E; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Chiba, K; Kurokawa, T; Matsushima, Y; Nakanishi, Y; Narita, Y; Shiroiwa, T; Urushihara, H | 1 |
| Anaya, P; Arrieta, O; Morales-Oyarvide, V; Polanco, AC; Ramírez-Tirado, LA | 1 |
| Banerjee, S; Carty, K; Davidson, S; Dive, C; Flubacher, M; Gourley, C; Hudson, E; Jackson, D; Jankowska, P; Lord, R; McCartney, E; McCormack, M; Paul, J; Powell, M; Rai, D; Reed, N; Symonds, RP; West, CML | 1 |
| Tewari, KS | 1 |
| Ahn, JH; Choi, CM; Choi, YJ; Kim, SW; Lee, DH; Lee, JS; Lee, SJ | 1 |
| Inoue, A; Kobayashi, K; Nukiwa, T; Watanabe, S | 1 |
| Bonerigo, S; Chung, CH; Cmelak, A; Gilbert, J; John, P; Kang, H; Kiess, A; Marur, S; Murphy, BA; Quon, H; Rudek, MA; Tsottles, N; Veasey, A | 1 |
| Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ | 1 |
| Clark, E; Cook, A; Eisenhauer, E; Embleton, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Parmar, MKB; Perren, TJ; Raja, F; Rustin, GJS; Stark, D; Swart, AM; Vaughan, M | 1 |
| Luo, Z; Nitin, N; Samadzadeh, KM | 1 |
| Lai, FC; Li, X; Lin, JB; Lin, JW; Lin, M; Liu, B; Luo, RG; Qiu, ML; Tu, YR | 1 |
| Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J | 1 |
| Blohmer, JU; Darb-Esfahani, S; Denkert, C; Dietel, M; Endris, V; Jackisch, C; Klare, P; Kümmel, S; Loi, S; Loibl, S; Möbs, M; Nekljudova, V; Reimer, T; Salat, C; Schem, C; Schmitt, W; Sinn, B; Sinn, P; Stenzinger, A; Tesch, H; Untch, M; von Minckwitz, G; Weichert, W | 1 |
| Hanaoka, J; Hayashi, H; Iihara, H; Itoh, Y; Kawaguchi, Y; Mizusaki, N; Sugiyama, T | 1 |
| Chewaskulyong, B; Fukuoka, M; Haddad, V; Han, B; Ichinose, Y; Margono, B; Mok, TS; Ohe, Y; Rukazenkov, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ; Young, H | 1 |
| Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G | 1 |
| Jean-Claude, B; Thibault, B | 1 |
| Chu, T; Dong, Y; Gu, A; Han, B; Jin, B; Lou, Y; Niu, Y; Pei, J; Shi, C; Wang, H; Xu, J; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhu, L | 1 |
| Breathnach, O; Carr, A; Crown, J; Duke, D; Eustace, AJ; Fay, J; Gallagher, W; Grogan, L; Gullo, G; Hambly, N; Hennessy, BT; Hill, AD; Kay, EW; Kelly, C; Kennedy, MJ; Madden, SF; Milewska, M; Moulton, B; O'Donovan, N; Power, C; Sheehan, KM; Teiserskiene, A; Toomey, S; Walshe, J | 1 |
| Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z | 1 |
| Li, B; Li, Y; Liu, Z; Shu, T; Wu, X | 1 |
| Ishimoto, O; Kawashima, Y; Kikuchi, T; Kobayashi, K; Maeno, Y; Masumoto, AI; Nukiwa, T; Sugawara, S; Watanabe, S; Yamaguchi, OU; Yoshizawa, H | 1 |
| Birtle, A; Casbard, A; Chester, J; Crabb, S; Elliott, T; Evans, L; Griffiths, G; Huang, C; Huddart, R; Jagdev, S; Jones, R; Lester, J; Madden, TA | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
19 review(s) available for quinazolines and carboplatin
| Article | Year |
|---|---|
[New trends in antineoplastic drug research].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Danazol; Fluorouracil; Folic Acid; Harringtonines; Humans; Organoplatinum Compounds; Quinazolines; Thymine Nucleotides | 1985 |
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Smoking | 2007 |
[Head and neck: molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Head and Neck Neoplasms; Humans; Paclitaxel; Quinazolines | 2007 |
[Case of bilateral pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple pulmonary metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Pneumothorax; Quinazolines | 2008 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
Systemic treatment of malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Pleura; Pleural Neoplasms; Quinazolines; Thiophenes; Treatment Outcome | 2012 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
89 trial(s) available for quinazolines and carboplatin
| Article | Year |
|---|---|
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2003 |
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; United States | 2003 |
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Quinazolines; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Gefitinib; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Treatment Outcome | 2005 |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2006 |
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation | 2006 |
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2008 |
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines | 2008 |
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Smoking; Treatment Outcome | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Remission Induction; Taxoids; Treatment Outcome | 2009 |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2009 |
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2009 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines | 2010 |
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (W
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Time Factors | 2011 |
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2010 |
Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2011 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult | 2010 |
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Research Design; Southwestern United States; Treatment Outcome | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2011 |
Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Patient Selection; Practice Patterns, Physicians'; Quinazolines; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; United States | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; ErbB Receptors; Europe; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Vimentin | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Outcome | 2011 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2012 |
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Smoking | 2012 |
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Endpoint Determination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quality of Life; Quinazolines; Treatment Outcome | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Quality of Life; Quinazolines | 2012 |
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cohort Studies; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2012 |
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Analysis | 2013 |
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome | 2012 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Quinazolines | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Platinum Compounds; Population Groups; Quinazolines | 2014 |
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Survival Analysis; Young Adult | 2014 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2014 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Pneumonectomy; Prospective Studies; Quinazolines; Survival Rate | 2014 |
A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2015 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Tegafur; Treatment Outcome | 2015 |
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines; Uterine Cervical Neoplasms | 2015 |
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcino
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quinazolines | 2015 |
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Quinazolines; Treatment Outcome | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Piperidines; Quinazolines; Treatment Outcome | 2017 |
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Quinazolines; Treatment Outcome | 2016 |
Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pleural Effusion, Malignant; Quinazolines | 2017 |
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2017 |
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction | 2017 |
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Point Mutation; Quinazolines | 2017 |
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Taxoids; Trastuzumab | 2017 |
Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2018 |
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Piperidines; Quinazolines; Treatment Outcome | 2020 |
62 other study(ies) available for quinazolines and carboplatin
| Article | Year |
|---|---|
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Survival Rate; Taxoids; Thiophenes; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab | 2005 |
[A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer].
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2006 |
Synchronous multiple primary lung cancers with different response to gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Quinazolines; Tomography, X-Ray Computed | 2006 |
[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Meningitis; Middle Aged; Neoplasm Proteins; Paclitaxel; Palliative Care; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Vinblastine; Vinorelbine | 2006 |
Contrasts, conflicts, and change: A case in cultural oncology.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Attitude to Health; Carboplatin; Cultural Characteristics; Erlotinib Hydrochloride; Family Relations; Female; Humans; Middle Aged; Paclitaxel; Physician-Patient Relations; Quinazolines; Thoracic Neoplasms | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
[Medical treatment for stage III non-small-cell lung cancer (NSCLC)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mitomycin; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate | 2007 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Prolonged response to gefitinib in bone metastasis.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Back Pain; Carboplatin; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms; Time Factors | 2009 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Cycle; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Taxoids | 2009 |
Generating genome-scale candidate gene lists for pharmacogenomics.
Topics: Anticoagulants; Antineoplastic Agents; Area Under Curve; Carboplatin; Deoxycytidine; Gefitinib; Gemcitabine; Gene Expression Regulation; Genes; Genome, Human; Humans; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Quinazolines; Warfarin | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
[Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Radiosurgery | 2009 |
[A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Neoplasms; Mutation; Paclitaxel; Quinazolines | 2009 |
Treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Proportional Hazards Models; Quinazolines; Survival Analysis | 2009 |
Treatment of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Paclitaxel; Proportional Hazards Models; Quinazolines | 2009 |
Treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2009 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
Serious hematologic complications following erlotinib treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Targeted therapy for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2011 |
Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Ultrasonography, Interventional | 2011 |
Molecular selection trumps clinical selection.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
Topics: Apoptosis; Blotting, Western; Carboplatin; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Glutamates; Guanine; Humans; Immunohistochemistry; Mesothelioma; Pemetrexed; Phosphorylation; Piperidines; Pleural Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
On Bayesian methods of exploring qualitative interactions for targeted treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Carboplatin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; ErbB Receptors; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pharmacogenetics; Quinazolines; Regression Analysis; Survival Analysis | 2012 |
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Tumor Burden | 2012 |
Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase B; Carboplatin; Carcinoma; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Female; Humans; Organophosphates; Ovarian Neoplasms; Polyploidy; Quinazolines | 2013 |
[Primary lateral sclerosis and lung adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Causality; Diagnosis, Differential; Dysarthria; Electromyography; Fatal Outcome; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Motor Neuron Disease; Motor Neurons; Multimodal Imaging; Paraneoplastic Syndromes, Nervous System; Pemetrexed; Pleural Effusion, Malignant; Positron-Emission Tomography; Quadriplegia; Quinazolines; Tomography, X-Ray Computed | 2013 |
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Predicting drug responsiveness in human cancers using genetically engineered mice.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium | 2014 |
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Support Techniques; DNA Mutational Analysis; Economics, Pharmaceutical; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Markov Chains; Mutation; Paclitaxel; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2015 |
Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Latin America; Lung Neoplasms; Male; Mexico; Models, Econometric; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2016 |
Clinical implications for cediranib in advanced cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines; Uterine Cervical Neoplasms | 2015 |
Rapid assessment of drug resistance of cancer cells to gefitinib and carboplatin using optical imaging.
Topics: Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gefitinib; Humans; Optical Imaging; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2016 |
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Neoplasm Invasiveness; Ovarian Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; src-Family Kinases; Tumor Cells, Cultured | 2017 |
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Female; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Middle Aged; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2017 |